pharmaphorum January 26, 2022
We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United States. So, what can we do to keep home-grown science on European soil?
From the Pfizer/BioNTech and Oxford/AstraZeneca vaccines to GSK’s lifesaving antibody treatments, European innovation has played a crucial role in the global response to COVID-19.
But while the pandemic triggered a boom in biotech initial public offerings, according to Hannah Kuchler, Global Pharmaceuticals Correspondent at the Financial Times (FT), the vast majority went public on the US’ NASDAQ.
“It highlighted, yet again, concerns about whether fantastic academic science is as easy to translate into companies in Europe as it is in the United...
Today's Sponsors
Today's Sponsor